The global asthma drugs market has been forecast to increase at a compound annual growth rate (CAGR) of 5.7% over the next five years, to increase from a market value of $15.3 billion recorded in 2012, to hit $20.2 billion by 2017.

1. Global asthma drugs market to hit $20.2 billion by 2017
Published: August 15th 2012
The global asthma drugs market has been forecast to increase at a compound annual growth rate
compound
(CAGR) of 5.7% over the next five years, to increase from a market value of $15.3 billion recorded in
2012, to hit $20.2 billion by 2017.
Asthma is a respiratory condition in which the airways become inflammed and constrict, usually in
response to one or more environmental triggers. As a serious and potentially fatal condition if left
untreated, asthma can be managed by avoiding triggers and with drug therapy.
Over 300 million people suffer from asthma, which translates to a drug market worth over $15
billion. While drugs to manage asthma have existed for several decades, pharmaceutical companies
have developed faster acting and more effective products over the years.
GlaxoSmithKline's Advair and AstraZeneca's Symbicort are the latest additions to the asthma drugs
additions
market, and are poised to take over the industry as older products go generic.
In the overall Asthma and COPD market, Advair remained the market leader with a value of $7,802
million in 2011, and Singulair was the second largest drug in terms of revenue at $5,479 million.
The chronic obstructive pulmonary disease (COPD) prescription drugs sector is expected to increase
from $5.3 billion in 2012 to $5.6 billion in 2017, a CAGR of 1.2%.
The global market for the two types of drugs combined was valued at $34.9 billion in 2011. This
figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five
five-year
compound annual growth rate (CAGR) of 4.4%.
Asthma and COPD are two diseases experiencing increasing prevalence globally due to a
prevalence
combination of factors, including a globally aging population, increasing pollution levels, an increase
in the number of people smoking and numerous heredity factors.
Even treatments within the global asthma drugs market enjoy tremendous commercial success,
tremendous
there still remains a perceived high level of unmet need in this market in terms of treatment options
for asthma and COPD patients.
Looking ahead, the global asthma drugs market looks set to change due to generic erosion and th
the
launch of new drug combinations with a longer duration of action and better safety and efficacy
profiles than existing drugs.
For more information on the global asthma drugs market see the latest
market,
research: http://www.companiesandmarkets.com/Market/Healthcare
http://www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market
Medical/Market-
Research/Global-Markets-for-Asthma
Asthma-and-COPD-Drugs/RPT661792
Author: Matt Bodimeade
Email: enquiries@companiesandmarkets.com
Published by: http://www.companiesandmarkets.com